RESUMEN
Mutations in SLC46A1 result in a defect of the proton coupled folate transporter (PCFT) and are the basis of hereditary folate malabsorption (HFM). Patients with HFM frequently present with neurodevelopmental delay and megaloblastic anemia. Some cases may be complicated by additional lymphopenia and immunodeficiency. We report a patient with a new homozygous mutation in the SLC46A1 gene. The boy presented with early-onset pancytopenia and secondary immunodeficiency. We provide clinical and molecular observations that extend the phenotypic description of HFM and highlight diagnostic as well as therapeutic pitfalls in this rare condition.
Asunto(s)
Deficiencia de Ácido Fólico/complicaciones , Síndromes de Inmunodeficiencia/etiología , Síndromes de Malabsorción/complicaciones , Pancitopenia/etiología , Adolescente , Adulto , Niño , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Infantile hemangioma (IH) is the most frequent vascular tumor of early childhood. Recently, propranolol, a nonselective ß1- and ß2-adrenoceptor inhibitor, was introduced into the therapy of severe proliferating IH with excellent results. However, the underlying mechanism of action of propranolol is still unclear. METHODS: We performed immunohistochemistry for cluster of differentiation 31 (CD31), D2-40, glucose transporter-1 (GLUT-1), and Ki67 in order to characterize 21 vascular anomalies (nine IH, seven venous malformations (VMs), and five lymphatic malformations (LMs)). Furthermore, we analyzed the expression of ß1-, ß2-, and ß3-adrenoceptor mRNA in these specimens as well as in hemangioma-derived stem cells by quantitative real-time PCR (qPCR). RESULTS: We show that the expression of ß1-adrenoceptor mRNA is 10.7-fold higher in IH independent of the proliferative or regressive phase as well as 2.5-fold higher in hemangioma-derived stem cells as compared with ß2-adrenoceptor mRNA. In LM, the expression of ß2-adrenoceptor mRNA was ninefold higher than that of ß1-adrenoceptor mRNA. VM showed low expression levels of all ß-adrenoceptor mRNAs, and ß3-adrenoceptor mRNA was hardly detectable in any specimens examined. CONCLUSION: These results provide the first evidence of distinctions between IH and vascular malformations with regard to ß-adrenoceptor subtype mRNA levels.
Asunto(s)
Hemangioma Capilar/genética , Células Madre Neoplásicas/metabolismo , Síndromes Neoplásicos Hereditarios/genética , ARN Mensajero/metabolismo , Receptores Adrenérgicos beta 1/genética , Malformaciones Vasculares/genética , Adolescente , Anticuerpos Monoclonales de Origen Murino , Células Cultivadas , Niño , Preescolar , Marcadores Genéticos , Transportador de Glucosa de Tipo 1/metabolismo , Hemangioma Capilar/metabolismo , Hemangioma Capilar/patología , Humanos , Inmunohistoquímica , Lactante , Recién Nacido , Antígeno Ki-67/metabolismo , Células Madre Neoplásicas/patología , Síndromes Neoplásicos Hereditarios/metabolismo , Síndromes Neoplásicos Hereditarios/patología , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores Adrenérgicos beta 2/genética , Receptores Adrenérgicos beta 3/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Malformaciones Vasculares/metabolismo , Malformaciones Vasculares/patologíaRESUMEN
Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (n = 1,328) or unrelated donors (n = 2,824) developing grade 3 or 4 aGvHD were included. In univariate analysis, the probability of TRM at 2 years was increased for countries with lower current Health Care Expenditure (HCE, p = 0.04), lower HCE as % of Gross Domestic Product per capita (p = 0.003) and lower values of the Human Development Index (p = 0.02). In a multivariate model, the risk of TRM was most strongly predicted by current HCE (HR = 0.76, p = 0.006). HCE >median was also associated with reduced risk of the overall mortality (HR 0.73, p = 0.0006) and reduced risk of treatment failure (either relapse or TRM; HR 0.77, p = 0.004). We conclude that country-specific socioeconomic factors, in particular current HCE, are strongly associated with survival of patients who experience severe aGvHD.
Asunto(s)
Enfermedad Injerto contra Huésped/epidemiología , Enfermedad Injerto contra Huésped/etiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Enfermedad Aguda , Adolescente , Adulto , Anciano , Progresión de la Enfermedad , Europa (Continente)/epidemiología , Femenino , Enfermedad Injerto contra Huésped/diagnóstico , Costos de la Atención en Salud , Encuestas de Atención de la Salud , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Mortalidad , Pronóstico , Sistema de Registros , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores Socioeconómicos , Trasplante Homólogo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Inhibition of the epidermal growth factor receptor (EGFR), using a tyrosine kinase inhibitor such as gefitinib, was suggested to be a new treatment approach for neuroblastoma. MATERIAL AND METHODS: EGFR expression and gene mutation were studied by reversetranscriptase-polxmerase chain reacting, fluorescence-activated cell sorting and gene sequencing in six neuroblastoma cell lines. In vitro cytotoxicity of gefitinib 0.1-10 microM alone or in combination with topotecan, vincristine and 9-cis retinoic acid (9cisRA) was determined by MTT proliferation assay. RESULTS: EGFR overexpression and gene mutations were absent in all cell lines tested. Inhibition of cell viability of 62-85% was found at 10 microM gefitinib, concentrations that, however, can clinically not be reached. In addition, gefitinib increased inhibitory effects of topotecan, vincristine and RA by 10-15% . CONCLUSION: Our in vitro data do not support the use of gefitinib as monotherapy in neuroblastoma and its chemosensitizing effects appear minor.
Asunto(s)
Receptores ErbB/antagonistas & inhibidores , Neuroblastoma/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/farmacología , Quinazolinas/farmacología , Antineoplásicos/farmacología , Western Blotting , Proliferación Celular/efectos de los fármacos , Receptores ErbB/genética , Receptores ErbB/metabolismo , Citometría de Flujo , Gefitinib , Humanos , Mutación/genética , Neuroblastoma/metabolismo , Neuroblastoma/patología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Topotecan/farmacología , Células Tumorales CultivadasRESUMEN
Myelodysplastic syndromes (MDS) and the mixed myelodysplastic/myeloproliferative disorder juvenile myelomonocytic leukaemia (JMML) are rare haematopoietic stem cell diseases in children. While MDS-initiating events remain largely obscure, a growing body of clinical, genetic and laboratory evidence suggests that JMML is, at least in part, caused by aberrant signal transduction resulting from mutations of components of the RAS signalling pathway. To date, haematopoietic stem cell transplantation cures more than half of children diagnosed with MDS or JMML. Research on genetic conditions predisposing to MDS in young age, such as inherited syndromes with bone marrow failure, may present important insights into MDS pathogenesis.
Asunto(s)
Leucemia Mielomonocítica Juvenil/genética , Síndromes Mielodisplásicos/genética , Niño , Aberraciones Cromosómicas , Humanos , Leucemia Mielomonocítica Juvenil/clasificación , Leucemia Mielomonocítica Juvenil/terapia , Mutación , Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/terapiaRESUMEN
In this study, we reviewed the history of 38 children with proliferating haemangiomas treated with systemic corticosteroids at our institution between 2000 and 2002. Prednisone was administered at an initial dose of 2 mg/kg per day for 2 weeks followed by a dose of 1 mg/kg per day for another 2-4 weeks and consecutive slow tapering over an additional 4-5 months. For 93% of the children, this protocol was successful in reducing the size of the haemangioma by more than 25% after 2 weeks of treatment. Side effects were moderate and reversible after cessation of therapy.
Asunto(s)
Corticoesteroides/uso terapéutico , Glucocorticoides/uso terapéutico , Hemangioma/tratamiento farmacológico , Prednisona/uso terapéutico , Corticoesteroides/administración & dosificación , Corticoesteroides/efectos adversos , Esquema de Medicación , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Hemangioma/clasificación , Hemangioma/fisiopatología , Humanos , Lactante , Masculino , Prednisona/administración & dosificación , Prednisona/efectos adversos , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
For the first time, we could detect lymph vessels in neuroblastoma (NB) by immunohistochemistry with the antibody D2_40. Furthermore, we demonstrate expression of the lymphangiogenic factors VEGF-C and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in NB in vitro and in vivo by RT-PCR. However, addition of recombinant human VEGF-C or -D results in the absence of autocrine growth stimulus in NB cells. Treatment of NB cells with retinoic acid did not lead to a change in VEGF-C or VEGF-D mRNA expression. Incubation of the NB cells Lan-5 with 5-Aza-2'-deoxycytidine led to the up-regulation of VEGF-C mRNA expression, suggesting that the promotor of VEGF-C is methylated. Finally, VEGF-C mRNA expression could be effectively down-regulated by transfection with a specific siRNA in the NB cells Kelly. We conclude that lymphangiogenesis is involved in NB biology and that siRNA directed against VEGF-C may have a future role in anti-lymphangiogenic strategies in NB.
Asunto(s)
Linfangiogénesis , Vasos Linfáticos/metabolismo , Vasos Linfáticos/patología , Neuroblastoma/metabolismo , Neuroblastoma/patología , Factor C de Crecimiento Endotelial Vascular/metabolismo , Humanos , Células Tumorales CultivadasRESUMEN
Neuroblastoma (NB) expresses the tyrosine kinase receptors c-Kit, PDGFR-alpha and -beta-targets for STI-571. We investigated a possible combination therapy of STI-571 with retinoic acid (RA) and gamma-irradiation on NB cell viability in vitro. Expression of tyrosine kinase receptors and their ligands was examined in 6 NB cell lines by RT-PCR and FACS. The effect on cell viability was determined by MTT assay. Cell viability of all 6 NB cell lines was significantly inhibited after treatment with 20 microM STI-571 for 72h, two cell lines responding already to 10 microM. Cell lines responded irrespective of their mRNA status or cell surface expression of c-Kit, PDGFR-alpha and -beta. Co-incubation with 9-cis RA sensitized cells to the inhibitory effects of STI-571. However, pre-treatment with 9-cis RA resulted in resistance of NB cell lines to STI-571 and gamma-irradiation. Treatment of NB with STI-571 in combination with 9-cis RA might be a therapeutic strategy for patients in consolidation therapy who have completed gamma-irradiation therapy.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/efectos de la radiación , Rayos gamma/uso terapéutico , Neuroblastoma/patología , Neuroblastoma/terapia , Piperazinas/administración & dosificación , Pirimidinas/administración & dosificación , Tretinoina/administración & dosificación , Benzamidas , Línea Celular Tumoral , Quimioterapia Adyuvante/métodos , Humanos , Mesilato de ImatinibRESUMEN
We report a neonate with hypertrophic cardiomyopathy and lethal myeloproliferative disorder with excessively proliferating immature erythroid precursors infiltrating non-hematopoietic organs. Mutational analysis uncovered a germline mutation in the Noonan syndrome/LEOPARD syndrome (NS/LS) gene PTPN11. In conclusion, this case report suggests that congenital myeloproliferative disorders in association with germline PTPN11 mutations may affect the erythroid lineage.
Asunto(s)
Síndrome de Noonan/diagnóstico , Diagnóstico Diferencial , Resultado Fatal , Mutación de Línea Germinal , Humanos , Recién Nacido , Masculino , Síndrome de Noonan/genéticaRESUMEN
A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of little importance in pediatric MDS. Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly.
Asunto(s)
Síndromes Mielodisplásicos/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Aberraciones Cromosómicas , Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas/mortalidad , Humanos , Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/genéticaRESUMEN
Juvenile myelomonocytic leukemia is an aggressive neoplasia of early childhood. Only allogeneic stem cell transplantation (SCT) offers long-term cure. In the absence of an HLA-matched family donor, early SCT from an unrelated donor is the treatment of choice for most children. With clear evidence of a graft-versus-leukemia effect and a high post-transplant relapse rate, the outcome of SCT depends, in part, on the management of immunosuppression during the procedure. The impact of pretransplant cytoreductive treatment, such as intensive chemotherapy, splenectomy, or 13-cis retinoic acid, is unclear. Hypersensitivity for granulocyte-macrophage colony-stimulating factor and pathologic activation of the Ras/MAPK pathway play an important role in the pathophysiology of juvenile myelomonocytic leukemia and provide the opportunity for several novel therapeutic approaches.
Asunto(s)
Leucemia Mielomonocítica Crónica/terapia , Preescolar , Trastornos de los Cromosomas/genética , Trastornos de los Cromosomas/fisiopatología , Trastornos de los Cromosomas/terapia , Regulación Leucémica de la Expresión Génica/genética , Efecto Injerto vs Leucemia/fisiología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Histocompatibilidad , Humanos , Lactante , Leucemia Mielomonocítica Crónica/genética , Leucemia Mielomonocítica Crónica/fisiopatología , Recuento de Leucocitos , Recurrencia , Trasplante de Células MadreRESUMEN
Juvenile myelomonocytic leukemia is an aggressive neoplasia of early childhood. Only allogeneic stem cell transplantation (SCT) offers a long-term cure. In the absence of an HLA-matched family donor, early SCT from an unrelated donor will be the treatment of choice for most children. With clear evidence of a graft-versus-leukemia effect and a high post-transplant relapse rate, outcome of SCT will depend, in part, on the management of immunosuppression during the procedure. The impact of pretransplant cytoreductive treatment, such as intensive chemotherapy, splenectomy, or 13-cis retinoic acid, is unclear. Hypersensitivity for granulocyte-macrophage colony-stimulating factor and pathologic activation of the Ras/MAPK pathway play an important role in the pathophysiology of juvenile myelomonocytic leukemia and will provide the opportunity for several novel therapy approaches.
Asunto(s)
Leucemia Mielomonocítica Aguda , Leucemia Mielomonocítica Crónica , Preescolar , Terapia Combinada , Trasplante de Células Madre Hematopoyéticas , Humanos , Lactante , Leucemia Mielomonocítica Aguda/patología , Leucemia Mielomonocítica Aguda/terapia , Leucemia Mielomonocítica Crónica/patología , Leucemia Mielomonocítica Crónica/terapiaRESUMEN
OBJECTIVE: Pearson bone marrow-pancreas syndrome (PS) is a rare, usually fatal mitochondrial disorder involving the hematopoietic system in early infancy. Due to the diversity of clinical symptoms, the diagnosis can be difficult. The authors describe a boy with severe hypoplastic anemia in whom extensive clinical, biochemical, and morphologic findings led to the diagnosis of PS, and molecular analysis revealed a novel deletion of mitochondrial DNA from nucleotide position 10.371 to 14.607. METHODS: The patient is a 2-year-old boy who presented at age 5 months with hypoplastic macrocytic anemia. His first months of life and the family history were uneventful. Extensive pretransfusion evaluations did not reveal a metabolic, infectious, or hematologic-neoplastic etiology, and he had no evidence of exocrine pancreatic insufficiency. However, a second bone marrow aspirate at age 7 months showed a reduced cell number, vacuolated erythroblasts and myeloblasts, and ringed sideroblasts, so PS was suspected. RESULTS: Additional molecular analysis from the boy's blood leukocytes revealed a deletion of mitochondrial DNA from nucleotide position 10.371 to 14.607, which was absent in his mother's blood cells, consistent with a sporadic mutation as commonly seen in PS. The muscle histology and the respiratory chain enzymes were normal. CONCLUSIONS: Mitochondriopathies should be considered in children with persistent non-neuromuscular symptoms such as unexplained refractory anemia. Due to the often-fatal course of PS, the rapid detection of mitochondrial DNA deletions is imperative for diagnosis and family counseling.